ID   ROCK2_HUMAN             Reviewed;        1388 AA.
AC   O75116; Q53QZ0; Q53SJ7; Q9UQN5;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 4.
DT   12-OCT-2022, entry version 215.
DE   RecName: Full=Rho-associated protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=Rho kinase 2;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase 2;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase II;
DE            Short=ROCK-II;
DE   AltName: Full=p164 ROCK-2;
GN   Name=ROCK2; Synonyms=KIAA0619;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-431.
RC   TISSUE=Brain;
RX   PubMed=9933571; DOI=10.1006/geno.1998.5344;
RA   Takahashi N., Tuiki H., Saya H., Kaibuchi K.;
RT   "Localization of the gene coding for ROCK II/Rho kinase on human chromosome
RT   2p24.";
RL   Genomics 55:235-237(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-431.
RC   TISSUE=Brain;
RX   PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   FUNCTION, AND INTERACTION WITH PPP1R12A.
RX   PubMed=10579722; DOI=10.1083/jcb.147.5.1023;
RA   Kawano Y., Fukata Y., Oshiro N., Amano M., Nakamura T., Ito M.,
RA   Matsumura F., Inagaki M., Kaibuchi K.;
RT   "Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by
RT   Rho-kinase in vivo.";
RL   J. Cell Biol. 147:1023-1038(1999).
RN   [5]
RP   CLEAVAGE BY GRANZYME B, MUTAGENESIS OF ASP-1131, AND FUNCTION.
RX   PubMed=15699075; DOI=10.1084/jem.20031877;
RA   Sebbagh M., Hamelin J., Bertoglio J., Solary E., Breard J.;
RT   "Direct cleavage of ROCK II by granzyme B induces target cell membrane
RT   blebbing in a caspase-independent manner.";
RL   J. Exp. Med. 201:465-471(2005).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EP300.
RX   PubMed=16574662; DOI=10.1074/jbc.m510954200;
RA   Tanaka T., Nishimura D., Wu R.C., Amano M., Iso T., Kedes L., Nishida H.,
RA   Kaibuchi K., Hamamori Y.;
RT   "Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase.";
RL   J. Biol. Chem. 281:15320-15329(2006).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NPM1.
RX   PubMed=17015463; DOI=10.1128/mcb.01383-06;
RA   Ma Z., Kanai M., Kawamura K., Kaibuchi K., Ye K., Fukasawa K.;
RT   "Interaction between ROCK II and nucleophosmin/B23 in the regulation of
RT   centrosome duplication.";
RL   Mol. Cell. Biol. 26:9016-9034(2006).
RN   [8]
RP   PHOSPHORYLATION AT TYR-722, AND DEPHOSPHORYLATION.
RX   PubMed=18559669; DOI=10.1083/jcb.200710187;
RA   Lee H.H., Chang Z.F.;
RT   "Regulation of RhoA-dependent ROCKII activation by Shp2.";
RL   J. Cell Biol. 181:999-1012(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH PPP1R12A.
RX   PubMed=19131646; DOI=10.1161/circresaha.108.188524;
RA   Wang Y., Zheng X.R., Riddick N., Bryden M., Baur W., Zhang X., Surks H.K.;
RT   "ROCK isoform regulation of myosin phosphatase and contractility in
RT   vascular smooth muscle cells.";
RL   Circ. Res. 104:531-540(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=19997641; DOI=10.1371/journal.pone.0008190;
RA   Lock F.E., Hotchin N.A.;
RT   "Distinct roles for ROCK1 and ROCK2 in the regulation of keratinocyte
RT   differentiation.";
RL   PLoS ONE 4:E8190-E8190(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   INTERACTION WITH CHORDC1.
RX   PubMed=20230755; DOI=10.1016/j.devcel.2009.12.020;
RA   Ferretti R., Palumbo V., Di Savino A., Velasco S., Sbroggio M.,
RA   Sportoletti P., Micale L., Turco E., Silengo L., Palumbo G., Hirsch E.,
RA   Teruya-Feldstein J., Bonaccorsi S., Pandolfi P.P., Gatti M., Tarone G.,
RA   Brancaccio M.;
RT   "Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and
RT   tumorigenesis.";
RL   Dev. Cell 18:486-495(2010).
RN   [15]
RP   PHOSPHORYLATION AT TYR-722.
RX   PubMed=20826462; DOI=10.1242/jcs.071555;
RA   Lee H.H., Tien S.C., Jou T.S., Chang Y.C., Jhong J.G., Chang Z.F.;
RT   "Src-dependent phosphorylation of ROCK participates in regulation of focal
RT   adhesion dynamics.";
RL   J. Cell Sci. 123:3368-3377(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH BRCA2.
RX   PubMed=21084279; DOI=10.1158/0008-5472.can-10-0030;
RA   Wang H.F., Takenaka K., Nakanishi A., Miki Y.;
RT   "BRCA2 and nucleophosmin coregulate centrosome amplification and form a
RT   complex with the Rho effector kinase ROCK2.";
RL   Cancer Res. 71:68-77(2011).
RN   [19]
RP   FUNCTION, INTERACTION WITH SORL1, AND TISSUE SPECIFICITY.
RX   PubMed=21147781; DOI=10.1074/jbc.m110.167239;
RA   Herskowitz J.H., Seyfried N.T., Gearing M., Kahn R.A., Peng J., Levey A.I.,
RA   Lah J.J.;
RT   "Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA
RT   alters amyloid-beta production.";
RL   J. Biol. Chem. 286:6117-6127(2011).
RN   [20]
RP   REVIEW.
RX   PubMed=12778124; DOI=10.1038/nrm1128;
RA   Riento K., Ridley A.J.;
RT   "Rocks: multifunctional kinases in cell behaviour.";
RL   Nat. Rev. Mol. Cell Biol. 4:446-456(2003).
RN   [21]
RP   REVIEW.
RX   PubMed=20803696; DOI=10.1002/cm.20472;
RA   Amano M., Nakayama M., Kaibuchi K.;
RT   "Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity.";
RL   Cytoskeleton 67:545-554(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1212; SER-1362 AND SER-1374,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [26]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-431; VAL-601 AND PRO-1194.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase which is a key regulator of actin cytoskeleton
CC       and cell polarity. Involved in regulation of smooth muscle contraction,
CC       actin cytoskeleton organization, stress fiber and focal adhesion
CC       formation, neurite retraction, cell adhesion and motility via
CC       phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN,
CC       MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4.
CC       Acts as a negative regulator of VEGF-induced angiogenic endothelial
CC       cell activation. Positively regulates the activation of p42/MAPK1-
CC       p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays
CC       an important role in the timely initiation of centrosome duplication.
CC       Inhibits keratinocyte terminal differentiation. May regulate closure of
CC       the eyelids and ventral body wall through organization of actomyosin
CC       bundles. Plays a critical role in the regulation of spine and synaptic
CC       properties in the hippocampus. Plays an important role in generating
CC       the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and
CC       vascular contractility by modulating the myosin light chain
CC       phosphorylation. {ECO:0000269|PubMed:10579722,
CC       ECO:0000269|PubMed:15699075, ECO:0000269|PubMed:16574662,
CC       ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:19131646,
CC       ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:21147781}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Activated by RHOA binding. Inhibited by Y-27632
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with IRS1 (By
CC       similarity). Interacts with RAF1 (By similarity). Interacts with RHOA
CC       (activated by GTP), RHOB and RHOC (By similarity). Interacts with
CC       PPP1R12A (PubMed:10579722, PubMed:19131646). Interacts with EP300
CC       (PubMed:16574662). Interacts with CHORDC1 (PubMed:20230755). Interacts
CC       with BRCA2 (PubMed:21084279). Interacts with NPM1; this interaction
CC       enhances ROCK2 activity (PubMed:17015463). Interacts with SORL1
CC       (PubMed:21147781). Interacts with PJVK (By similarity).
CC       {ECO:0000250|UniProtKB:P70336, ECO:0000250|UniProtKB:Q28021,
CC       ECO:0000250|UniProtKB:Q62868, ECO:0000269|PubMed:10579722,
CC       ECO:0000269|PubMed:16574662, ECO:0000269|PubMed:17015463,
CC       ECO:0000269|PubMed:19131646, ECO:0000269|PubMed:20230755,
CC       ECO:0000269|PubMed:21084279, ECO:0000269|PubMed:21147781}.
CC   -!- INTERACTION:
CC       O75116; P05067: APP; NbExp=6; IntAct=EBI-366288, EBI-77613;
CC       O75116; O60674: JAK2; NbExp=2; IntAct=EBI-366288, EBI-518647;
CC       O75116; P40763: STAT3; NbExp=3; IntAct=EBI-366288, EBI-518675;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}. Nucleus. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome.
CC       Note=Cytoplasmic, and associated with actin microfilaments and the
CC       plasma membrane. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain (at protein level).
CC       {ECO:0000269|PubMed:21147781}.
CC   -!- DOMAIN: An interaction between Thr-414 and Asp-48 is essential for
CC       kinase activity and dimerization. {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Tyr-722 reduces its binding to RHOA and is
CC       crucial for focal adhesion dynamics. Dephosphorylation by PTPN11
CC       stimulates its RHOA binding activity. {ECO:0000269|PubMed:18559669,
CC       ECO:0000269|PubMed:20826462}.
CC   -!- PTM: Cleaved by granzyme B during apoptosis. This leads to constitutive
CC       activation of the kinase and membrane blebbing.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAX93049.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAA31594.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ROCK2ID43474ch2p25.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D87931; BAA75636.1; -; mRNA.
DR   EMBL; AB014519; BAA31594.2; ALT_INIT; mRNA.
DR   EMBL; AC018463; AAX93049.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC099344; AAY14825.1; -; Genomic_DNA.
DR   CCDS; CCDS42654.1; -.
DR   RefSeq; NP_001308572.1; NM_001321643.1.
DR   RefSeq; NP_004841.2; NM_004850.4.
DR   PDB; 4L6Q; X-ray; 2.79 A; A/B=19-417.
DR   PDB; 4WOT; X-ray; 2.93 A; A/B/C/D=22-417.
DR   PDB; 5U7Q; X-ray; 3.15 A; A/B/C/D=23-417.
DR   PDB; 5U7R; X-ray; 3.33 A; A/B/C/D=23-417.
DR   PDB; 6ED6; X-ray; 2.86 A; A/B=27-417.
DR   PDB; 6P5M; X-ray; 2.65 A; A/B/C/D=18-417.
DR   PDB; 6P5P; X-ray; 3.30 A; A/B/C/D=18-417.
DR   PDB; 7JNT; X-ray; 2.21 A; A/B/C/D/E/F/G/H=19-417.
DR   PDB; 7JOV; X-ray; 2.59 A; A/B/C/D/E/F/G/H=23-417.
DR   PDBsum; 4L6Q; -.
DR   PDBsum; 4WOT; -.
DR   PDBsum; 5U7Q; -.
DR   PDBsum; 5U7R; -.
DR   PDBsum; 6ED6; -.
DR   PDBsum; 6P5M; -.
DR   PDBsum; 6P5P; -.
DR   PDBsum; 7JNT; -.
DR   PDBsum; 7JOV; -.
DR   AlphaFoldDB; O75116; -.
DR   SMR; O75116; -.
DR   BioGRID; 114860; 118.
DR   CORUM; O75116; -.
DR   IntAct; O75116; 38.
DR   MINT; O75116; -.
DR   STRING; 9606.ENSP00000317985; -.
DR   BindingDB; O75116; -.
DR   ChEMBL; CHEMBL2973; -.
DR   DrugBank; DB16703; Belumosudil.
DR   DrugBank; DB08162; Fasudil.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB13931; Netarsudil.
DR   DrugBank; DB13165; Ripasudil.
DR   DrugBank; DB08756; Y-27632.
DR   DrugCentral; O75116; -.
DR   GuidetoPHARMACOLOGY; 1504; -.
DR   GlyGen; O75116; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O75116; -.
DR   MetOSite; O75116; -.
DR   PhosphoSitePlus; O75116; -.
DR   SwissPalm; O75116; -.
DR   BioMuta; ROCK2; -.
DR   EPD; O75116; -.
DR   jPOST; O75116; -.
DR   MassIVE; O75116; -.
DR   MaxQB; O75116; -.
DR   PaxDb; O75116; -.
DR   PeptideAtlas; O75116; -.
DR   PRIDE; O75116; -.
DR   ProteomicsDB; 49773; -.
DR   Antibodypedia; 2077; 728 antibodies from 44 providers.
DR   DNASU; 9475; -.
DR   Ensembl; ENST00000315872.11; ENSP00000317985.6; ENSG00000134318.15.
DR   GeneID; 9475; -.
DR   KEGG; hsa:9475; -.
DR   MANE-Select; ENST00000315872.11; ENSP00000317985.6; NM_004850.5; NP_004841.2.
DR   UCSC; uc002rbd.2; human.
DR   CTD; 9475; -.
DR   DisGeNET; 9475; -.
DR   GeneCards; ROCK2; -.
DR   HGNC; HGNC:10252; ROCK2.
DR   HPA; ENSG00000134318; Low tissue specificity.
DR   MIM; 604002; gene.
DR   neXtProt; NX_O75116; -.
DR   OpenTargets; ENSG00000134318; -.
DR   PharmGKB; PA34624; -.
DR   VEuPathDB; HostDB:ENSG00000134318; -.
DR   eggNOG; KOG0612; Eukaryota.
DR   GeneTree; ENSGT01030000234517; -.
DR   HOGENOM; CLU_000288_140_0_1; -.
DR   InParanoid; O75116; -.
DR   OMA; WTFENLR; -.
DR   OrthoDB; 759391at2759; -.
DR   PhylomeDB; O75116; -.
DR   TreeFam; TF313551; -.
DR   PathwayCommons; O75116; -.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013026; RHOB GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   Reactome; R-HSA-9013422; RHOBTB1 GTPase cycle.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SignaLink; O75116; -.
DR   SIGNOR; O75116; -.
DR   BioGRID-ORCS; 9475; 41 hits in 1129 CRISPR screens.
DR   ChiTaRS; ROCK2; human.
DR   GenomeRNAi; 9475; -.
DR   Pharos; O75116; Tclin.
DR   PRO; PR:O75116; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O75116; protein.
DR   Bgee; ENSG00000134318; Expressed in calcaneal tendon and 198 other tissues.
DR   ExpressionAtlas; O75116; baseline and differential.
DR   Genevisible; O75116; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0072518; F:Rho-dependent protein serine/threonine kinase activity; IMP:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; NAS:ProtInc.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; NAS:ARUK-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISS:BHF-UCL.
DR   GO; GO:0031032; P:actomyosin structure organization; IBA:GO_Central.
DR   GO; GO:0003180; P:aortic valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0097746; P:blood vessel diameter maintenance; ISS:ARUK-UCL.
DR   GO; GO:1905145; P:cellular response to acetylcholine; ISS:ARUK-UCL.
DR   GO; GO:0071394; P:cellular response to testosterone stimulus; IMP:UniProtKB.
DR   GO; GO:0051298; P:centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0048598; P:embryonic morphogenesis; IBA:GO_Central.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0000281; P:mitotic cytokinesis; IBA:GO_Central.
DR   GO; GO:0044788; P:modulation by host of viral process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0061157; P:mRNA destabilization; ISS:ARUK-UCL.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:1903347; P:negative regulation of bicellular tight junction assembly; IGI:UniProtKB.
DR   GO; GO:0070168; P:negative regulation of biomineral tissue development; ISS:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:0035509; P:negative regulation of myosin-light-chain-phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0045019; P:negative regulation of nitric oxide biosynthetic process; IMP:ARUK-UCL.
DR   GO; GO:0150033; P:negative regulation of protein localization to lysosome; IMP:ARUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:ARUK-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IMP:ARUK-UCL.
DR   GO; GO:1902993; P:positive regulation of amyloid precursor protein catabolic process; IMP:ARUK-UCL.
DR   GO; GO:1902004; P:positive regulation of amyloid-beta formation; IMP:ARUK-UCL.
DR   GO; GO:1902961; P:positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process; IMP:ARUK-UCL.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:ARUK-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0010825; P:positive regulation of centrosome duplication; IEA:InterPro.
DR   GO; GO:0032723; P:positive regulation of connective tissue growth factor production; ISS:ARUK-UCL.
DR   GO; GO:1905205; P:positive regulation of connective tissue replacement; ISS:ARUK-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0090271; P:positive regulation of fibroblast growth factor production; ISS:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:ARUK-UCL.
DR   GO; GO:1902966; P:positive regulation of protein localization to early endosome; IMP:ARUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IMP:BHF-UCL.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0110061; P:regulation of angiotensin-activated signaling pathway; ISS:ARUK-UCL.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:1901888; P:regulation of cell junction assembly; IBA:GO_Central.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:1900037; P:regulation of cellular response to hypoxia; ISS:ARUK-UCL.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; TAS:UniProtKB.
DR   GO; GO:1903140; P:regulation of establishment of endothelial barrier; IMP:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; TAS:UniProtKB.
DR   GO; GO:0045616; P:regulation of keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0031644; P:regulation of nervous system process; ISS:ARUK-UCL.
DR   GO; GO:0051246; P:regulation of protein metabolic process; ISS:ARUK-UCL.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; TAS:UniProtKB.
DR   GO; GO:1990776; P:response to angiotensin; ISS:ARUK-UCL.
DR   GO; GO:0002931; P:response to ischemia; ISS:ARUK-UCL.
DR   GO; GO:0071559; P:response to transforming growth factor beta; ISS:ARUK-UCL.
DR   GO; GO:0007266; P:Rho protein signal transduction; IBA:GO_Central.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0006939; P:smooth muscle contraction; TAS:UniProtKB.
DR   CDD; cd00029; C1; 1.
DR   CDD; cd11638; HR1_ROCK2; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR011072; HR1_rho-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR020684; ROCK1/ROCK2.
DR   InterPro; IPR037311; ROCK2_HR1.
DR   InterPro; IPR015008; ROCK_Rho-bd_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08912; Rho_Binding; 1.
DR   PIRSF; PIRSF037568; Rho_kinase; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51860; REM_1; 1.
DR   PROSITE; PS51859; RHO_BD; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Biological rhythms; Cell membrane; Coiled coil;
KW   Cytoplasm; Cytoskeleton; Kinase; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..1388
FT                   /note="Rho-associated protein kinase 2"
FT                   /id="PRO_0000086625"
FT   DOMAIN          92..354
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          357..425
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          497..573
FT                   /note="REM-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          979..1047
FT                   /note="RhoBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01206"
FT   DOMAIN          1150..1349
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   ZN_FING         1260..1315
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          1..27
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          363..784
FT                   /note="Interaction with PPP1R12A"
FT   REGION          373..420
FT                   /note="Interaction with NPM1"
FT                   /evidence="ECO:0000269|PubMed:17015463"
FT   REGION          979..1047
FT                   /note="RHOA binding"
FT                   /evidence="ECO:0000250"
FT   REGION          1345..1388
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          429..1024
FT                   /evidence="ECO:0000255"
FT   COILED          1053..1131
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        1363..1388
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        214
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         98..106
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         121
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            1131..1132
FT                   /note="Cleavage; by granzyme B"
FT   MOD_RES         414
FT                   /note="Phosphothreonine; by ROCK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q62868"
FT   MOD_RES         722
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:18559669,
FT                   ECO:0000269|PubMed:20826462"
FT   MOD_RES         1137
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         1212
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1374
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         431
FT                   /note="T -> N (in dbSNP:rs2230774)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:9734811, ECO:0000269|PubMed:9933571"
FT                   /id="VAR_041062"
FT   VARIANT         601
FT                   /note="D -> V (in dbSNP:rs35768389)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041063"
FT   VARIANT         1083
FT                   /note="K -> M (in dbSNP:rs34945852)"
FT                   /id="VAR_057110"
FT   VARIANT         1194
FT                   /note="S -> P (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041064"
FT   MUTAGEN         1131
FT                   /note="D->A: Abolishes cleavage by granzyme B."
FT                   /evidence="ECO:0000269|PubMed:15699075"
FT   CONFLICT        83
FT                   /note="R -> K (in Ref. 1; BAA75636)"
FT                   /evidence="ECO:0000305"
FT   HELIX           26..35
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           43..57
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           62..64
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           66..85
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           89..91
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   STRAND          92..100
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   STRAND          105..111
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   TURN            112..114
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   STRAND          117..124
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           125..130
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           137..146
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   STRAND          155..160
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   STRAND          162..169
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           177..183
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           188..207
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           217..219
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   STRAND          220..222
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   STRAND          228..230
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   STRAND          243..245
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   TURN            254..256
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           259..262
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           264..266
FT                   /evidence="ECO:0007829|PDB:5U7Q"
FT   STRAND          269..272
FT                   /evidence="ECO:0007829|PDB:6P5M"
FT   HELIX           274..289
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           299..307
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           309..312
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   TURN            317..319
FT                   /evidence="ECO:0007829|PDB:6P5M"
FT   HELIX           323..332
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   TURN            336..338
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   TURN            340..343
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           346..349
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           352..354
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   TURN            361..363
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           364..366
FT                   /evidence="ECO:0007829|PDB:7JNT"
FT   HELIX           408..410
FT                   /evidence="ECO:0007829|PDB:7JNT"
SQ   SEQUENCE   1388 AA;  160900 MW;  876240F410C2487E CRC64;
     MSRPPPTGKM PGAPETAPGD GAGASRQRKL EALIRDPRSP INVESLLDGL NSLVLDLDFP
     ALRKNKNIDN FLNRYEKIVK KIRGLQMKAE DYDVVKVIGR GAFGEVQLVR HKASQKVYAM
     KLLSKFEMIK RSDSAFFWEE RDIMAFANSP WVVQLFYAFQ DDRYLYMVME YMPGGDLVNL
     MSNYDVPEKW AKFYTAEVVL ALDAIHSMGL IHRDVKPDNM LLDKHGHLKL ADFGTCMKMD
     ETGMVHCDTA VGTPDYISPE VLKSQGGDGF YGRECDWWSV GVFLYEMLVG DTPFYADSLV
     GTYSKIMDHK NSLCFPEDAE ISKHAKNLIC AFLTDREVRL GRNGVEEIRQ HPFFKNDQWH
     WDNIRETAAP VVPELSSDID SSNFDDIEDD KGDVETFPIP KAFVGNQLPF IGFTYYRENL
     LLSDSPSCRE TDSIQSRKNE ESQEIQKKLY TLEEHLSNEM QAKEELEQKC KSVNTRLEKT
     AKELEEEITL RKSVESALRQ LEREKALLQH KNAEYQRKAD HEADKKRNLE NDVNSLKDQL
     EDLKKRNQNS QISTEKVNQL QRQLDETNAL LRTESDTAAR LRKTQAESSK QIQQLESNNR
     DLQDKNCLLE TAKLKLEKEF INLQSALESE RRDRTHGSEI INDLQGRICG LEEDLKNGKI
     LLAKVELEKR QLQERFTDLE KEKSNMEIDM TYQLKVIQQS LEQEEAEHKA TKARLADKNK
     IYESIEEAKS EAMKEMEKKL LEERTLKQKV ENLLLEAEKR CSLLDCDLKQ SQQKINELLK
     QKDVLNEDVR NLTLKIEQET QKRCLTQNDL KMQTQQVNTL KMSEKQLKQE NNHLMEMKMN
     LEKQNAELRK ERQDADGQMK ELQDQLEAEQ YFSTLYKTQV RELKEECEEK TKLGKELQQK
     KQELQDERDS LAAQLEITLT KADSEQLARS IAEEQYSDLE KEKIMKELEI KEMMARHKQE
     LTEKDATIAS LEETNRTLTS DVANLANEKE ELNNKLKDVQ EQLSRLKDEE ISAAAIKAQF
     EKQLLTERTL KTQAVNKLAE IMNRKEPVKR GNDTDVRRKE KENRKLHMEL KSEREKLTQQ
     MIKYQKELNE MQAQIAEESQ IRIELQMTLD SKDSDIEQLR SQLQALHIGL DSSSIGSGPG
     DAEADDGFPE SRLEGWLSLP VRNNTKKFGW VKKYVIVSSK KILFYDSEQD KEQSNPYMVL
     DIDKLFHVRP VTQTDVYRAD AKEIPRIFQI LYANEGESKK EQEFPVEPVG EKSNYICHKG
     HEFIPTLYHF PTNCEACMKP LWHMFKPPPA LECRRCHIKC HKDHMDKKEE IIAPCKVYYD
     ISTAKNLLLL ANSTEEQQKW VSRLVKKIPK KPPAPDPFAR SSPRTSMKIQ QNQSIRRPSR
     QLAPNKPS
//
